Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Tumor heterogeneity impairs immunogenicity in mismatch repair deficient tumors

Nature Genetics volume 55, pages 1610–1612 (2023)Cite this article

Subjects

DNA mismatch repair deficiency (MMRd) is associated with elevated tumor mutational burden (TMB) and exceptional immunotherapy responses, yet some patients experience no clinical benefit. Recent work proposes that high intra-tumoral heterogeneity can offset immunogenicity in sporadic MMRd, suggesting a potential mechanism of immunotherapy failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overview of the study.

References

  1. Litchfield, K. et al. Cell 184, 596–614 e514 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Westcott, P. M. K. et al. Nat. Genet. https://doi.org/10.1038/s41588-023-01499-4 (2023).

    Article  PubMed  Google Scholar 

  4. Jackson, E. L. et al. Genes Dev. 15, 3243–3248 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. DuPage, M. & Jacks, T. Curr. Opin. Immunol. 25, 192–199 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McFadden, D. G. et al. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Westcott, P. M. et al. Nature 517, 489–492 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. Wolf, Y. et al. Cell 179, 219–235 e221 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Germano, G. et al. Nature 552, 116–120 (2017).

    Article  CAS  PubMed  Google Scholar 

  10. Gejman, R. S. et al. Elife 7, e41090 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  11. McGranahan, N. et al. Science 351, 1463–1469 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Le, D. T. et al. Science 357, 409–413 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. Nat. Rev. Cancer 20, 218–232 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cercek, A. et al. N. Engl. J. Med. 386, 2363–2376 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chalabi, M. et al. Nat. Med. 26, 566–576 (2020).

    Article  CAS  PubMed  Google Scholar 

  16. Mandal, R. et al. Science 364, 485–491 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pre-Cancer Immunology Laboratory, UCL Cancer Institute, London, UK

    James L. Reading

  2. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK

    James L. Reading, Deborah R. Caswell & Charles Swanton

  3. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

    Deborah R. Caswell & Charles Swanton

Authors
  1. James L. Reading
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah R. Caswell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Swanton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Swanton.

Ethics declarations

Competing interests

Please see Supplementary Information for details.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reading, J.L., Caswell, D.R. & Swanton, C. Tumor heterogeneity impairs immunogenicity in mismatch repair deficient tumors. Nat Genet 55, 1610–1612 (2023). https://doi.org/10.1038/s41588-023-01492-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-023-01492-x

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer